Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 11Leukemia, Myeloid, Acute 5Uveal Melanoma 4Prostatic Neoplasms 4Myelodysplastic Syndromes 4Uterine Cervical Neoplasms 3Sarcoma 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Gastrointestinal Stromal Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Gliosarcoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

durvalumab 7Carboplatin 7Docetaxel 6Paclitaxel 5Nivolumab 5talazoparib 4linifanib 4Cisplatin 4trifluridine tipiracil drug combination 3tremelimumab 3tislelizumab 3depatuxizumab 3ST 1481 3S 1 (combination) 3Panobinostat 3Gemcitabine 3zimberelimab 2toripalimab 2olaparib 2motesanib diphosphate 2mogamulizumab 2TAS-114 2Sorafenib 2Rifampin 2PM 01183 2Oxaliplatin 2MLN 8237 2Itraconazole 2Injections 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumors × CTLA-4 Antigen × Clear all
NCT03545971 2023-02-28

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
53 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡